Big Data, Digital Health & Analytics 

Come and listen to speakers who are shaping technological innovation and harnessing digital health, analytics and AI to improve outcomes in access, pricing and evidence

BIG DATA, DIGITAL HEALTH & ANALYTICS, Wednesday 18 March 2020

Registration & refreshments

Morning Plenary

Erik Van Den Berg
09:00

Innovation in industry and practical considerations for biotechs

Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Ion Agirrezabal
09:20

Trends in modelling approaches for successful reimbursement of ATMPs

Ion Agirrezabal, Senior Consultant, Covance Market Access And Phase Iv Solutions, Covance Market Access
Bharat Tewarie
09:40

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

10:00

Reserved for Life Science Dynamics

10:20

Speed Networking

10:40

Morning refreshments

David Thompson
11:20

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Thomas Mueller
11:40

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

round tables
12:00

Roundtables

Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock

Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.

Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter

Michael Schroter, Partner, Viopas Partners

Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian

Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie

Roundtable 14: Indication based pricing- where are we?
Nicki Catterick

Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group

Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oresta Piniazhko

Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine

Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster

Douglas Foerster, Head Market Access Europe And Row, Santhera

Roundtable 17: Working together with NGOs, Advocates, Pharma & Government to improve outcomes for families?
Edmund Lim

Edmund Lim, Co-Founder, We CARE Journey

Roundtable 18: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay

Sagie Pillay, Chief Operating Officer, Wits Health Consortium

Roundtable 19: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch

Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc

Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos

Chris Pashos, Vice President Of Global Evidence Strategy, AbbVie

Roundtable 20: Branded combo-pricing: Where to next?
Yves Samel

Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer

Roundtable 21: Exploring Patient Access in Belgium: challenges and opportunities
Katrien Van Geyt

Katrien Van Geyt, Head Of Market Access, Belgium And Luxembourg, Takeda

Roundtable 22: Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Marcus Gaurdian

Marcus Gaurdian, Chief Operating Officer, EUnetHTA

Roundtable 23: Exploring orphan drugs in emerging markets
Lisette Kaskens

Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications

Roundtable 24: Developments in pricing and patient access for speciality treatments
Keith White

Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals

Roundtable 25: Reserved for Syneos Health
Roundtable 26: Reserved for Life Science Dynamics
Roundtable 27: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan

Gomathi Kaliappan, Global Market Access (Health Systems Strategy, Value Recognition), Roche

Roundtable 28: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu

Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)

Roundtable 29: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Julien Patris

Julien Patris, Associate Director Of Market Access And Policy For Europe And Canada, Alnylam

Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Jolanda Koenders

Jolanda Koenders, Head Of Market Access Netherlands, Takeda

Roundtable 30: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich

Adam Plich, Managing Director, Plich Advisory

Roundtable 32: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon

Giovanny Leon, Pricing And Market Access Director For Latin America And Canada, Novartis AG

Roundtable 33: Access and pricing considerations for CAR-T development
Nuno Prego Ramos

Nuno Prego Ramos, Chief Executive Officer, CellmAbs

Roundtable 34: Exploring Free of Charge supply model for an orphan drug at public healthcare coverage in Argentina
Marcelo Sal

Marcelo Sal, Head Of Market Access And Pricing, Argentina, PTC Therapeutics

Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Lindsay Weaver

Lindsay Weaver, Chief Executive Officer, Metabolic Support UK

Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo

Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh

Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin

Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement

Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate

Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara

12:50

Networking lunch

BIG DATA, DIGITAL HEALTH & ANALYTICS

Role of Digital & Big Data Analytics in Evidence

Igor Rudychev
BIG DATA, DIGITAL HEALTH & ANALYTICS
14:15

From Digital To Big Data Analytics & AI In Real World Data

BIG DATA, DIGITAL HEALTH & ANALYTICS
14:35

Sponsor presentation

Nadeem Ashraf
BIG DATA, DIGITAL HEALTH & ANALYTICS
14:55

Diabetes care in the world of digital health: What does the evidence say?

BIG DATA, DIGITAL HEALTH & ANALYTICS

Innovation in Access, Pricing & Diagnostics

Sandro Cesaro-Tadic
BIG DATA, DIGITAL HEALTH & ANALYTICS
15:15

Chair’s remarks

Laura O'Hanlon
BIG DATA, DIGITAL HEALTH & ANALYTICS
15:40

Access and pricing considerations in the world of innovative diagnostics

Jaume Vidal
BIG DATA, DIGITAL HEALTH & ANALYTICS
16:00

How transparency in R&D can improve access conditions?

16:20

Afternoon Refreshment Break

BIG DATA, DIGITAL HEALTH & ANALYTICS

Strategic Insight & Digital Medicines

Oliver Gassner
BIG DATA, DIGITAL HEALTH & ANALYTICS
16:55

Digital Medicines: Where are we now and what next

Hans Hofstraat
BIG DATA, DIGITAL HEALTH & ANALYTICS
17:15

Exploring the world of digital healthcare and how we can improve outcomes in market access and evidence

Ali Ciger
BIG DATA, DIGITAL HEALTH & ANALYTICS
17:35

Commercial initiatives within the digital space

17:55

Close of conference and networking drinks reception

last published: 20/Nov/19 09:55

BIG DATA, DIGITAL HEALTH & ANALYTICS, Thursday 19 March 2020

Morning Plenary

09:20

Sponsor presentation

Panel discussion
10:20

Morning refreshments

round tables
11:00

Roundtables

Roundtable 10: How to establish a market access department from scratch?
Michael Müller

Michael Müller, Head Of Market Access, Western Europe, SUN Pharma

Roundtable 12: Exploring the international reference pricing landscape
Tanya Aiden

Tanya Aiden, Global Products Lead, BIOCAD

Roundtable 13: Patient Assistance Programs and Access Structure in the US
Kankendria Ingram

Kankendria Ingram, Independent, Independent

Roundtable 14: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics
Benjamin Gannon

Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics

Roundtable 15: Market access, Pricing, Payer & HTA developments for the Nordic Region
Sune Lindgaard

Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark

Roundtable 16: Real world data and its utility in HTA decisions
Madhusudan Kabra

Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical

Roundtable 17: Patient based generated evidence
David Elvira

David Elvira, Heads Eu Public Affairs, Sanofi

Roundtable 18: Market Access and pricing considerations for Spain
Carme Pinyol

Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre

Roundtable 19: Importance and requirements of registry data in HTA processes for orphan drugs across Europe
Ulrike Beckert

Ulrike Beckert, Senior Patient Access Manager Dach, Sobi - Swedish Orphan Biovitrum AB (publ)

Roundtable 20: Exploring innovative reimbursement models for Advanced Therapy Medicinal Products
Carlo Incerti

Carlo Incerti, Operating Partner, Forbion

Roundtable 21: Market access considerations for oncology therapeutics
Adam Nosal

Adam Nosal, Head Of Market Access, Oncology Europe, AstraZeneca

Roundtable 22: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan

Niri Bhimsan, Head - Health Technology Assessment, Discovery Health

Roundtable 23: Exploring the long-term sustainability in the world of biosimilars
Diogo Piedade

Diogo Piedade, Health Economics Advisor, Medicines for Europe

Roundtable 24: The evolving perspective of price transparency
Matt Slabbert

Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals

Roundtable 25: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell

Warren Cowell, Market Access Director, Shionogi Inc

Roundtable 26: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver

Inneke Van De Vijver, Strategic Advisor – Reimbursement Pharmaceuticals, N.I.H.D.I.

Roundtable 27: Reserved for Lifescience Dynamics
Roundtable 28: Reserved for Syneos Health
Roundtable 29: Exploring repurposed products for rare diseases
Amer Omar

Amer Omar, Senior Director, Lupin

Roundtable 5: Exploring the evolution of the value framework to assess drugs in Italy
Americo Cicchetti

Americo Cicchetti, Director, Universita Cattolica Del Sacro Cuore

Roundtable 6: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Roundtable 7: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert

Sue Naeyaert, Vice President Global Government Affairs, Policy And Pharmacoeconomics Biosimilars, Fresenius Kabi

Roundtable 8: Accelerating Access to treatments for Rare Diseases
Gina Ewy

Gina Ewy, Head Of Global Market Access, Hansa Biopharma

Roundtable 9: How to involve patients in drug research and market access?
Dorinda Silva

Dorinda Silva, Volunteer Patient Advocate, Portuguese Association for CDG and other Rare Metabolic Diseases

Roundtables 2: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Irina Odnoletkova

Irina Odnoletkova, Vice President Health Technology Assessment, Apogenix Gmbh

Roundtables 3: Exploring innovative payment and evidence development models for rare diseases
Simon Shohet

Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen

13:05

Networking Lunch

15:10

Afternoon Refreshments

last published: 20/Nov/19 09:55

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com